Provider Notifications

Welcome to Provider Notifications — an online resource where providers can find the latest news and updates about HPSM. In March 2026, notifications switched to a fully digital blog format. To read notifications prior to March 1, 2026, go to the Notification Archive.

Changes to Prior Authorization Required List Effective 6/1/2026

Dear provider, 

Here are changes to the Health Plan of San Mateo’s (HPSM’s) prior authorization required list. Find the current list on the Provider Authorizations page.

4 conditional codes had their requirements updated: 

CPT Code

Description

A0428

Ambulance service, basic life support, non-emergency transport (BLS)

Auth not required for hospital to nursing facility (modifier HN), hospital to custodial facility (modifier HE), hospital to residence (HR), or hospital to hospital (modifier HH) rides, hospital to diagnostic (modifier HD). 

Q5136

INJ. DENOSUMAB-BBDZ 1 MG

Claims for 60 units per DOS do NOT require a PA; claims for over 60 units require a PA. 

Q5157

INJ DENOSUMAB-BMWO 1 MG

Claims for 60 units per DOS do NOT require a PA; claims for over 60 units require a PA. 

Q5158

INJ DENOSUMAB-BNHT 1 MG

Claims for 60 units per DOS do NOT require a PA; claims for over 60 units require a PA. 

41 codes were added to the prior authorization required list:

CPT Code

Description

0562U 

Oncology (solid tumor), targeted genomic sequence analysis, 33 genes, detection of single-nucleotide variants (SNVs), insertions and deletions, copy-number amplifications, and translocations in human genomic circulating cell-free DNA, plasma, reported as presence of actionable variants 

0569U 

Oncology (solid tumor), next-generation sequencing analysis of tumor methylation markers (>20000 differentially methylated regions) present in cell-free circulating tumor DNA (ctDNA), whole blood, algorithm reported as presence or absence of ctDNA with tumor fraction, if appropriate 

0570U 

Neurology (traumatic brain injury), analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), immunoassay, whole blood or plasma, individual components reported with the overall result of elevated or nonelevated based on threshold comparison 

0571U 

Oncology (solid tumor), DNA (80 genes) and RNA (10 genes), by next-generation sequencing, plasma, including single-nucleotide variants, insertions/deletions, copy-number alterations, microsatellite instability, and fusions, reported as clinically actionable variants 

87513 

Infectious agent detection by nucleic acid (DNA or RNA); Helicobacter pylori (H. pylori), clarithromycin resistance, amplified probe technique 

A2040 

Microlyte PainGuard, per sq cm 

A2041 

Foundation DRS+ Duo, per sq cm 

A2042 

Foundation DRS+ Solo, per sq cm 

A2043 

BIOBRANE, per sq cm 

A2044 

BIOBRANE Glove, each 

A2045 

NovaShield or NovoGen Wound Matrix, per sq cm 

A4479 

Electronic transanal irrigation system, includes electronic pump, water reservoir, tubing, and accessories, without catheter, any type 

A8005 

Powered, cable driven grip assist glove, hand, finger, includes microprocessor, pressure sensors, all components and accessories, custom fitted 

A8806 

Powered, cable driven grip assist glove, hand, finger, includes pressure sensors, glove replacement only 

C8010 

Percutaneous placement of permanent common carotid embolic protection device, including all system components and imaging guidance; bilateral 

C9309 

Onasemnogene abeparvovec-brve (Itvisma) 

G0681 

Application of a premarket approval (PMA), 510(k), 361 human cells, tissues or cellular and tissue-based products (HCT/P) nonsheet form skin substitute for a wound surface area up to 100 sq cm; first 25 sq cm or less of wound surface area 

G0682 

Application of a premarket approval (PMA), 510(k), 361 human cells, tissues or cellular and tissue-based products (HCT/P) nonsheet form skin substitute for a wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (list separately in addition to code for primary procedure) 

G0683 

Application of a premarket approval (PMA), 510(k), 361 human cells, tissues or cellular and tissue-based products (HCT/P) nonsheet form skin substitute graft for a wound surface greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children 

G0684 

Application of a premarket approval (PMA), 510(k), 361 human cells, tissues or cellular and tissue-based products (HCT/P) nonsheet form skin substitute graft for a wound surface greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure) 

J2506 

INJ PEGFILGRAST EX BIO 0.5MG 

J3404 

Zopapogene imadenovec-drba (Papzimeos) 

L2221 

Addition to lower extremity orthosis, ankle system, microprocessor-controlled feature plantarflexion and/or dorsiflexion, includes power source 

Q4418 

BioLab Membrane Wrap Flow, per sq cm (add-on, list separately in addition to primary procedure) 

Q4419 

BioLab Membrane Wrap Lite Flow, per sq cm (add-on, list separately in addition to primary procedure) 

Q4421 

BioLab Membrane Wrap Solo, per sq cm (add-on, list separately in addition to primary procedure) 

Q4422 

A/C Wrap, per sq cm (add-on, list separately in addition to primary procedure) 

Q4423 

BioLab Tri-Membrane Wrap Flow, per sq cm (add-on, list separately in addition to primary procedure) 

Q4424 

Revive FT, per sq cm (add-on, list separately in addition to primary procedure) 

Q4425 

Revive TL, per sq cm (add-on, list separately in addition to primary procedure) 

Q4426 

DermaBind TL + or DermaBind TL X, per sq cm (add-on, list separately in addition to primary procedure) 

Q4427 

DermaBind DL N, DermaBind DL +, or DermaBind DL X, per sq cm (add-on, list separately in addition to primary procedure) 

Q4428 

DermaBind SL N, DermaBind SL +, or DermaBind SL X, per sq cm (add-on, list separately in addition to primary procedure) 

Q4429 

DermaBind CH N or DermaBind CH X, per sq cm (add-on, list separately in addition to primary procedure) 

Q4435 

Renati Membrane, per sq cm (add-on, list separately in addition to primary procedure) 

Q4436 

Renati AC Membrane, per sq cm (add-on, list separately in addition to primary procedure) 

Q4437 

Revival AC, per sq cm (add-on, list separately in addition to primary procedure) 

Q4438 

Pretect, per sq cm (add-on, list separately in addition to primary procedure) 

Q4439 

InstaGraft, per sq cm (add-on, list separately in addition to primary procedure) 

Q4440 

CuraMatrix, per sq cm (add-on, list separately in addition to primary procedure) 

Q5117 

INJ., KANJINTI, 10 MG 

49 codes were removed from the list for no longer requiring prior authorization:

CPT Code

Description

17311

Mohs micrographic technique

17312

MOHS ADDL STAGE

17313

MOHS 1 STAGE T/A/L

17314

MOHS ADDL STAGE T/A/L

17315

MOHS SURG ADDL BLOCK

27486

REVISION OF TOTAL KNEE ARTHROPLASTY, WITH OR WITHOUT ALLOGRAFT; 1 COMPONENT

27487

REVISION OF TOTAL KNEE ARTHROPLASTY, WITH OR WITHOUT ALLOGRAFT; FEMORAL AND ENTIRE TIBIAL COMPONENT

27488

REMOVAL OF PROSTHESIS, INCLUDING TOTAL KNEE PROSTHESIS, METHYLMETHACRYLATE WITH OR WITHOUT INSERTION OF SPACER, KNEE

81260

IKBKAP Gene

81400

MOPATH PROCEDURE LEVEL 1

81401

MOPATH PROCEDURE LEVEL 2

81402

MOPATH PROCEDURE LEVEL 3

81403

MOPATH PROCEDURE LEVEL 4

81404

MOPATH PROCEDURE LEVEL 5

81405

MOPATH PROCEDURE LEVEL 6

81406

MOPATH PROCEDURE LEVEL 7

81407

MOPATH PROCEDURE LEVEL 8

81408

MOPATH PROCEDURE LEVEL 9

0034U

TPMT, GENE ANALYSIS, COMMON VARIANTS

C9145

Injection, aprepitant, (Aponvie), 1 mg

E0168

COMMODE CHAIR XTRA WIDE&/HEVY DUTY

E0297

HOS BED TOT ELEC W/O RAIL/MATTRSS

G0154

HHCP-SVS OF RN,EA 15 MI

J0348

ANIDULAFUNGIN INJECTION (ERAXIS)

J0884

INJECTION, ARGATROBAN (ACOVA), 1 MG (FOR ESRD ON DIALYSIS)

J0885

Injection, epoetin alfa (EPOGEN, PROCRIT), (for non-ESRD use), 1000 units

J1740

IBANDRONATE SODIUM INJECTION (BONIVA)

J2248

MICAFUNGIN SODIUM INJECTION (MYCAMINE)

J2430

PAMIDRONATE DISODIUM /30 MG (AREDIA)

J2562

PLERIXAFOR INJECTION (MOZOBIL)

J3243

TIGECYCLINE INJECTION (TYGACIL)

J9033

BENDAMUSTINE INJECTION

J9041

BORTEZOMIB INJECTION (VELCADE)

J9155

DEGARELIX INJECTION (FIRMAGON)

J9225

HISTRELIN IMPLANT (VANTAS)

J9226

HISTRELIN IMPLANT (SUPPRELIN LA)

J9297

PEMETREXED (PEMFEXYTM, SANDOZ)

J9330

TEMSIROLIMUS INJECTION (TORISEL)

L6000

Partial hand, thumb remaining

L6010

Partial hand, little and/or ring finger remaining

L6020

Partial hand, no finger remaining

Q0138

Injection, ferumoxytol (Feraheme), for treatment of iron deficiency anemia, 1 mg (non-esrd use)

Q0139

Injection, ferumoxytol (Feraheme), for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)

Q2050

INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL

Q4081

Injection, epoetin alfa (EPOGEN, PROCRIT), 100 units (for ESRD on dialysis)

Q5105

Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units

Q5106

Injection, epoetin alfa-epbx, biosimilar, (Retacrit) (for non-ESRD use), 1000 units

Q5151

Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg

Q9997

Ustekinumab-ttwe (PYZCHIVA®) IV

For questions, contact the HPSM Provider Services department at [email protected].

Thank you,
The Health Plan of San Mateo